Showing posts with label access to healthcare and meds. Show all posts
Showing posts with label access to healthcare and meds. Show all posts

Tuesday, February 10, 2026

Trump Administration to Cut $600 Million in Health Funding From Four States; The New York Times, February 9, 2026

 , The New York Times; Trump Administration to Cut $600 Million in Health Funding From Four States

The states, all led by Democrats, used the grants to support a wide variety of functions, including H.I.V. prevention and surveillance.

"The Trump administration plans to rescind $600 million in public health funds from four states led by Democrats because it finds the grants “inconsistent with agency priorities,” according to documents reviewed by The New York Times.

The programs slated to be cut are in California, Colorado, Illinois and Minnesota. They include grants to state and local public health departments as well as to some nongovernmental organizations. A list of the cuts was shared with relevant congressional committees on Monday.

The funds are administered through the Centers for Disease Control and Prevention. They include grants given to states for a variety of purposes, including hiring staffs, modernizing data systems and managing disease outbreaks. Some programs are aimed at the needs of specific communities.

Some of the cuts will be finalized this week and others over the coming weeks, totaling roughly $600 million. The figure was first reported by The New York Post."

Thursday, March 31, 2016

GlaxoSmithKline to 'drop patents in poor countries for better drug access'; BBC News, 3/31/16

BBC News; GlaxoSmithKline to 'drop patents in poor countries for better drug access' :
"Pharmaceutical firm GlaxoSmithKline has said it wants to make it easier for manufacturers in the world's poorest countries to copy its medicines. The British company said it would not file patents in these countries.
Chief executive Sir Andrew Witty said he wanted to take a "graduated" approach to the company's "intellectual property" based on the wealth of nations around the globe.
Experts have described the plans as "brave and positive".
GSK hopes that by removing any fear of it filing for patent protection in poorer countries it will allow independent companies to make and sell versions of its drugs in those areas, thereby widening the public access to them."